Contact:

The Quigley Corporation Targets ALS Medication for Over-the-Counter Distribution

DOYLESTOWN, PA, July 16, 2002 - The Quigley Corporation (Nasdaq: QGLY) today announced that it had concluded that its patent pending QR-334 formulation for relief of Sialorrhea may qualify for sale as an over-the-counter (OTC) medication. The Company intends to work with associations representing ALS, Parkinson's and other relevant illnesses to develop immediate consumer awareness of this medication and to launch the national rollout of the product as quickly as possible.

"The over-the-counter market may prove to be a more viable approach to bringing the product to the marketplace more quickly and effectively, and could result in a new revenue stream for the Company," said Guy J. Quigley, Chairman, President and Chief Executive Officer of the Company.

Sialorrhea, or excess secretions of the salivary glands, is suffered by approximately 3,000,000 people afflicted by diseases including Amyotrophic Lateral Sclerosis (ALS, commonly known as Lou Gehrig's Disease), Cerebral Palsy, Parkinson's Disease, and Muscular Dystrophy. This condition can cause potentially life-threatening conditions including lung congestion and choking.

Last week, the Company announced that clinical trials of the Company's patented QR-334 Formulation have been arranged under the direction of Dr. Stanley H. Appel, Professor and Chairman of the Department of Neurology at the Baylor College of Medicine, and will commence later this month.

The Quigley Corporation (NASDAQ: QGLY) is a leading developer and marketer of diversified health products including the Cold-Eeze® family of patented zinc gluconate glycine (ZIGG™) lozenges, gums and sugar free tablets. Cold- Eeze is the only (ZIGG™) lozenge proven in two double-blind studies to reduce the duration of the common cold from 7.6 to 4.4 days or by 42%. In addition to Over-the-counter (OTC) products, the Company has formed Quigley Pharma Inc. (http://www.QuigleyPharma.com), a wholly owned ethical pharmaceutical subsidiary, to introduce a line of patented prescription drugs. The Quigley Corporation's customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies.

Certain statements in this press release are ``forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.